Effect of 1,25,28-trihydroxyvitamin D2 and 1,24,25-trihydroxyvitamin D3 on intestinal calbindin-D9K mRNA and protein: is there a correlation with intestinal calcium transport?
Although analogs and metabolites of vitamin D have been tested for their calciotropic activity, very little information has been available concerning the effects of these compounds on gene expression. In this study one analog of vitamin D, 1,25,28-trihydroxyvitamin D2 [1,25,28-(OH)3D2], and one metabolite, 1,24,25-trihydroxyvitamin D3 [1,24,25-(OH)3D3], were tested for their effect on intestinal calbindin-D9K mRNA and protein as well as for their effect on intestinal calcium absorption and bone calcium mobilization. These compounds were also evaluated for their ability to compete for rat intestinal 1,25-(OH)2D3 receptor sites and to induce differentiation of human leukemia (HL-60) cells as indicated by reduction of nitro blue tetrazolium. In vivo studies involved intrajugular injection of 12.5 ng 1,25-(OH)2D3 or test compound to vitamin D-deficient rats and sacrifice after 18 h. 1,25,28-Trihydroxyvitamin D2 had no effect on intestinal calcium absorption, bone calcium mobilization, or intestinal calbindin-D9K protein and mRNA. Competitive binding to 1,25-(OH)2D3 receptors was 0.8% of that observed using 1,25-(OH)2D3. However, 20- and 40-fold higher doses of 1,25,28-(OH)3D2 (250 and 500 ng) resulted in significant inductions in calbindin-D9K protein and mRNA (3.5 to 7.4-fold), although doses as high as 800 ng were found to have no effect on intestinal calcium absorption or bone calcium mobilization.(ABSTRACT TRUNCATED AT 250 WORDS)
Wang
Y Z
YZ
Department of Biochemistry and Molecular Biology, University of Medicine and Dentistry of New Jersey Medical School and Graduate School of Biomedical Sciences, Newark.
Li
H
H
Bruns
M E
ME
Uskokovic
M
M
Truitt
G A
GA
Horst
R
R
Reinhardt
T
T
Christakos
S
S
D015652:25-Hydroxyvitamin D 2 / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D001667:Binding, Competitive; D001692:Biological Transport / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D064026:Calbindins; D002117:Calcitriol / Q000378:metabolism / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D002454:Cell Differentiation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004386:Duodenum / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D006887:Hydroxycholecalciferols / Q000378:metabolism / Q000494:pharmacology*; D007408:Intestinal Absorption / Q000187:drug effects; D008297:Male; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D018167:Receptors, Calcitriol / Q000378:metabolism; D064030:S100 Calcium Binding Protein G / Q000235:genetics / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D014808:Vitamin D Deficiency
D064026:Calbindins; D006887:Hydroxycholecalciferols; D012333:RNA, Messenger; D018167:Receptors, Calcitriol; D064030:S100 Calcium Binding Protein G; C576506:S100G protein, human; C576508:S100g protein, rat; C085676:1,25,28-trihydroxyvitamin D 2; D015652:25-Hydroxyvitamin D 2; C013721:1,24,25-trihydroxyvitamin D3; D002117:Calcitriol; D002118:Calcium